**FOI 23/335 – Public Assessment Report - Bibecfo 200/6 mcg per actuation pressurised inhalation solution PLGB 36390/0393**

**REQUEST**
**9 May 2023**

Please can you provide me a copy of the Public Assessment report associated with the above MA held by Cipla (EU) Ltd. that was approved by the MHRA on 20/03/2023. Unfortunately, this doesn't appear to be published on your products web page and I'm aware that this product doesn't currently hold a European Licence.

**MHRA RESPONSE**
**22 May 2023**

Thank you for your request under FOI, a draft PAR for Bibecfo 200/6 mcg per actuation pressurised inhalation solution PLGB 36390/0393 has been prepared and was sent for your review this morning. A PAR for the 100/6 strength product is also in the process of being drafted.

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date you receive this response and addressed to: info@mhra.gov.uk
If you remain dissatisfied following any internal review, you may ask the Information Commissioner (ICO) to decide on whether or not we have interpreted the FOIA correctly in dealing with the request and subsequent internal review. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The ICO's address is:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Yours sincerely

MHRA Customer Experience Centre
Communications and engagement team

**MHRA FURTHER RESPONSE**
**5 June 2023**

Following our earlier correspondence the PARs for both strengths are now available online, please find the documents at the below link:

MHRA Products | Search results